Global RNA-based Therapeutics Drug Market Growth (Status and Outlook) 2026-2032
The global RNA-based Therapeutics Drug market size is predicted to grow from US$ 13040 million in 2025 to US$ 16910 million in 2032; it is expected to grow at a CAGR of 3.8% from 2026 to 2032.
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
LPI (LP Information)' newest research report, the “RNA-based Therapeutics Drug Industry Forecast” looks at past sales and reviews total world RNA-based Therapeutics Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected RNA-based Therapeutics Drug sales for 2026 through 2032. With RNA-based Therapeutics Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA-based Therapeutics Drug industry.
This Insight Report provides a comprehensive analysis of the global RNA-based Therapeutics Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RNA-based Therapeutics Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNA-based Therapeutics Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA-based Therapeutics Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA-based Therapeutics Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA-based Therapeutics Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.
The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.
LPI (LP Information)' newest research report, the “RNA-based Therapeutics Drug Industry Forecast” looks at past sales and reviews total world RNA-based Therapeutics Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected RNA-based Therapeutics Drug sales for 2026 through 2032. With RNA-based Therapeutics Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA-based Therapeutics Drug industry.
This Insight Report provides a comprehensive analysis of the global RNA-based Therapeutics Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RNA-based Therapeutics Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNA-based Therapeutics Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA-based Therapeutics Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA-based Therapeutics Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA-based Therapeutics Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Antisense Oligonucleotides (ASO)
- siRNA
- mRNA
- Neuromuscular Diseases
- hATTR
- COVID-19
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- CureVac
- Regulus Therapeutics
- ProQR
- Secarna
- MiNA Therapeutics
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA-based Therapeutics Drug Market Size (2021-2032)
2.1.2 RNA-based Therapeutics Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for RNA-based Therapeutics Drug by Country/Region (2021, 2025 & 2032)
2.2 RNA-based Therapeutics Drug Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 mRNA
2.2.4 RNA-based Therapeutics Drug Market Size by Type
2.2.4.1 RNA-based Therapeutics Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
2.3 RNA-based Therapeutics Drug Segment by Application
2.3.1 Neuromuscular Diseases
2.3.2 hATTR
2.3.3 COVID-19
2.3.4 Other
2.3.5 RNA-based Therapeutics Drug Market Size by Application
2.3.5.1 RNA-based Therapeutics Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
3 RNA-BASED THERAPEUTICS DRUG MARKET SIZE BY PLAYER
3.1 RNA-based Therapeutics Drug Market Size Market Share by Player
3.1.1 Global RNA-based Therapeutics Drug Revenue by Player (2021-2026)
3.1.2 Global RNA-based Therapeutics Drug Revenue Market Share by Player (2021-2026)
3.2 Global RNA-based Therapeutics Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RNA-BASED THERAPEUTICS DRUG BY REGION
4.1 RNA-based Therapeutics Drug Market Size by Region (2021-2026)
4.2 Global RNA-based Therapeutics Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas RNA-based Therapeutics Drug Market Size Growth (2021-2026)
4.4 APAC RNA-based Therapeutics Drug Market Size Growth (2021-2026)
4.5 Europe RNA-based Therapeutics Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa RNA-based Therapeutics Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas RNA-based Therapeutics Drug Market Size by Country (2021-2026)
5.2 Americas RNA-based Therapeutics Drug Market Size by Type (2021-2026)
5.3 Americas RNA-based Therapeutics Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA-based Therapeutics Drug Market Size by Region (2021-2026)
6.2 APAC RNA-based Therapeutics Drug Market Size by Type (2021-2026)
6.3 APAC RNA-based Therapeutics Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe RNA-based Therapeutics Drug Market Size by Country (2021-2026)
7.2 Europe RNA-based Therapeutics Drug Market Size by Type (2021-2026)
7.3 Europe RNA-based Therapeutics Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA-based Therapeutics Drug by Region (2021-2026)
8.2 Middle East & Africa RNA-based Therapeutics Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa RNA-based Therapeutics Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RNA-BASED THERAPEUTICS DRUG MARKET FORECAST
10.1 Global RNA-based Therapeutics Drug Forecast by Region (2027-2032)
10.1.1 Global RNA-based Therapeutics Drug Forecast by Region (2027-2032)
10.1.2 Americas RNA-based Therapeutics Drug Forecast
10.1.3 APAC RNA-based Therapeutics Drug Forecast
10.1.4 Europe RNA-based Therapeutics Drug Forecast
10.1.5 Middle East & Africa RNA-based Therapeutics Drug Forecast
10.2 Americas RNA-based Therapeutics Drug Forecast by Country (2027-2032)
10.2.1 United States Market RNA-based Therapeutics Drug Forecast
10.2.2 Canada Market RNA-based Therapeutics Drug Forecast
10.2.3 Mexico Market RNA-based Therapeutics Drug Forecast
10.2.4 Brazil Market RNA-based Therapeutics Drug Forecast
10.3 APAC RNA-based Therapeutics Drug Forecast by Region (2027-2032)
10.3.1 China RNA-based Therapeutics Drug Market Forecast
10.3.2 Japan Market RNA-based Therapeutics Drug Forecast
10.3.3 Korea Market RNA-based Therapeutics Drug Forecast
10.3.4 Southeast Asia Market RNA-based Therapeutics Drug Forecast
10.3.5 India Market RNA-based Therapeutics Drug Forecast
10.3.6 Australia Market RNA-based Therapeutics Drug Forecast
10.4 Europe RNA-based Therapeutics Drug Forecast by Country (2027-2032)
10.4.1 Germany Market RNA-based Therapeutics Drug Forecast
10.4.2 France Market RNA-based Therapeutics Drug Forecast
10.4.3 UK Market RNA-based Therapeutics Drug Forecast
10.4.4 Italy Market RNA-based Therapeutics Drug Forecast
10.4.5 Russia Market RNA-based Therapeutics Drug Forecast
10.5 Middle East & Africa RNA-based Therapeutics Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market RNA-based Therapeutics Drug Forecast
10.5.2 South Africa Market RNA-based Therapeutics Drug Forecast
10.5.3 Israel Market RNA-based Therapeutics Drug Forecast
10.5.4 Turkey Market RNA-based Therapeutics Drug Forecast
10.6 Global RNA-based Therapeutics Drug Forecast by Type (2027-2032)
10.7 Global RNA-based Therapeutics Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market RNA-based Therapeutics Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics RNA-based Therapeutics Drug Product Offered
11.1.3 Sarepta Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals RNA-based Therapeutics Drug Product Offered
11.2.3 Ionis Pharmaceuticals RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam RNA-based Therapeutics Drug Product Offered
11.3.3 Alnylam RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen RNA-based Therapeutics Drug Product Offered
11.4.3 Biogen RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku RNA-based Therapeutics Drug Product Offered
11.5.3 Nippon Shinyaku RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi RNA-based Therapeutics Drug Product Offered
11.6.3 Sobi RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis RNA-based Therapeutics Drug Product Offered
11.7.3 Novartis RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 BioNTech
11.8.1 BioNTech Company Information
11.8.2 BioNTech RNA-based Therapeutics Drug Product Offered
11.8.3 BioNTech RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 BioNTech Main Business Overview
11.8.5 BioNTech Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer RNA-based Therapeutics Drug Product Offered
11.9.3 Pfizer RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Information
11.10.2 Moderna Therapeutics RNA-based Therapeutics Drug Product Offered
11.10.3 Moderna Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Moderna Therapeutics Main Business Overview
11.10.5 Moderna Therapeutics Latest Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Information
11.11.2 Jazz Pharmaceuticals RNA-based Therapeutics Drug Product Offered
11.11.3 Jazz Pharmaceuticals RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jazz Pharmaceuticals Main Business Overview
11.11.5 Jazz Pharmaceuticals Latest Developments
11.12 CureVac
11.12.1 CureVac Company Information
11.12.2 CureVac RNA-based Therapeutics Drug Product Offered
11.12.3 CureVac RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 CureVac Main Business Overview
11.12.5 CureVac Latest Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Information
11.13.2 Regulus Therapeutics RNA-based Therapeutics Drug Product Offered
11.13.3 Regulus Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Regulus Therapeutics Main Business Overview
11.13.5 Regulus Therapeutics Latest Developments
11.14 ProQR
11.14.1 ProQR Company Information
11.14.2 ProQR RNA-based Therapeutics Drug Product Offered
11.14.3 ProQR RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 ProQR Main Business Overview
11.14.5 ProQR Latest Developments
11.15 Secarna
11.15.1 Secarna Company Information
11.15.2 Secarna RNA-based Therapeutics Drug Product Offered
11.15.3 Secarna RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Secarna Main Business Overview
11.15.5 Secarna Latest Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Information
11.16.2 MiNA Therapeutics RNA-based Therapeutics Drug Product Offered
11.16.3 MiNA Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 MiNA Therapeutics Main Business Overview
11.16.5 MiNA Therapeutics Latest Developments
11.17 Sylentis
11.17.1 Sylentis Company Information
11.17.2 Sylentis RNA-based Therapeutics Drug Product Offered
11.17.3 Sylentis RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sylentis Main Business Overview
11.17.5 Sylentis Latest Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Information
11.18.2 Arrowhead RNA-based Therapeutics Drug Product Offered
11.18.3 Arrowhead RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Arrowhead Main Business Overview
11.18.5 Arrowhead Latest Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Information
11.19.2 Silence Therapeutics RNA-based Therapeutics Drug Product Offered
11.19.3 Silence Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Silence Therapeutics Main Business Overview
11.19.5 Silence Therapeutics Latest Developments
11.20 Dicerna
11.20.1 Dicerna Company Information
11.20.2 Dicerna RNA-based Therapeutics Drug Product Offered
11.20.3 Dicerna RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Dicerna Main Business Overview
11.20.5 Dicerna Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA-based Therapeutics Drug Market Size (2021-2032)
2.1.2 RNA-based Therapeutics Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for RNA-based Therapeutics Drug by Country/Region (2021, 2025 & 2032)
2.2 RNA-based Therapeutics Drug Segment by Type
2.2.1 Antisense Oligonucleotides (ASO)
2.2.2 siRNA
2.2.3 mRNA
2.2.4 RNA-based Therapeutics Drug Market Size by Type
2.2.4.1 RNA-based Therapeutics Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
2.3 RNA-based Therapeutics Drug Segment by Application
2.3.1 Neuromuscular Diseases
2.3.2 hATTR
2.3.3 COVID-19
2.3.4 Other
2.3.5 RNA-based Therapeutics Drug Market Size by Application
2.3.5.1 RNA-based Therapeutics Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.5.2 Global RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
3 RNA-BASED THERAPEUTICS DRUG MARKET SIZE BY PLAYER
3.1 RNA-based Therapeutics Drug Market Size Market Share by Player
3.1.1 Global RNA-based Therapeutics Drug Revenue by Player (2021-2026)
3.1.2 Global RNA-based Therapeutics Drug Revenue Market Share by Player (2021-2026)
3.2 Global RNA-based Therapeutics Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RNA-BASED THERAPEUTICS DRUG BY REGION
4.1 RNA-based Therapeutics Drug Market Size by Region (2021-2026)
4.2 Global RNA-based Therapeutics Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas RNA-based Therapeutics Drug Market Size Growth (2021-2026)
4.4 APAC RNA-based Therapeutics Drug Market Size Growth (2021-2026)
4.5 Europe RNA-based Therapeutics Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa RNA-based Therapeutics Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas RNA-based Therapeutics Drug Market Size by Country (2021-2026)
5.2 Americas RNA-based Therapeutics Drug Market Size by Type (2021-2026)
5.3 Americas RNA-based Therapeutics Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA-based Therapeutics Drug Market Size by Region (2021-2026)
6.2 APAC RNA-based Therapeutics Drug Market Size by Type (2021-2026)
6.3 APAC RNA-based Therapeutics Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe RNA-based Therapeutics Drug Market Size by Country (2021-2026)
7.2 Europe RNA-based Therapeutics Drug Market Size by Type (2021-2026)
7.3 Europe RNA-based Therapeutics Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA-based Therapeutics Drug by Region (2021-2026)
8.2 Middle East & Africa RNA-based Therapeutics Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa RNA-based Therapeutics Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RNA-BASED THERAPEUTICS DRUG MARKET FORECAST
10.1 Global RNA-based Therapeutics Drug Forecast by Region (2027-2032)
10.1.1 Global RNA-based Therapeutics Drug Forecast by Region (2027-2032)
10.1.2 Americas RNA-based Therapeutics Drug Forecast
10.1.3 APAC RNA-based Therapeutics Drug Forecast
10.1.4 Europe RNA-based Therapeutics Drug Forecast
10.1.5 Middle East & Africa RNA-based Therapeutics Drug Forecast
10.2 Americas RNA-based Therapeutics Drug Forecast by Country (2027-2032)
10.2.1 United States Market RNA-based Therapeutics Drug Forecast
10.2.2 Canada Market RNA-based Therapeutics Drug Forecast
10.2.3 Mexico Market RNA-based Therapeutics Drug Forecast
10.2.4 Brazil Market RNA-based Therapeutics Drug Forecast
10.3 APAC RNA-based Therapeutics Drug Forecast by Region (2027-2032)
10.3.1 China RNA-based Therapeutics Drug Market Forecast
10.3.2 Japan Market RNA-based Therapeutics Drug Forecast
10.3.3 Korea Market RNA-based Therapeutics Drug Forecast
10.3.4 Southeast Asia Market RNA-based Therapeutics Drug Forecast
10.3.5 India Market RNA-based Therapeutics Drug Forecast
10.3.6 Australia Market RNA-based Therapeutics Drug Forecast
10.4 Europe RNA-based Therapeutics Drug Forecast by Country (2027-2032)
10.4.1 Germany Market RNA-based Therapeutics Drug Forecast
10.4.2 France Market RNA-based Therapeutics Drug Forecast
10.4.3 UK Market RNA-based Therapeutics Drug Forecast
10.4.4 Italy Market RNA-based Therapeutics Drug Forecast
10.4.5 Russia Market RNA-based Therapeutics Drug Forecast
10.5 Middle East & Africa RNA-based Therapeutics Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market RNA-based Therapeutics Drug Forecast
10.5.2 South Africa Market RNA-based Therapeutics Drug Forecast
10.5.3 Israel Market RNA-based Therapeutics Drug Forecast
10.5.4 Turkey Market RNA-based Therapeutics Drug Forecast
10.6 Global RNA-based Therapeutics Drug Forecast by Type (2027-2032)
10.7 Global RNA-based Therapeutics Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market RNA-based Therapeutics Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics RNA-based Therapeutics Drug Product Offered
11.1.3 Sarepta Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Information
11.2.2 Ionis Pharmaceuticals RNA-based Therapeutics Drug Product Offered
11.2.3 Ionis Pharmaceuticals RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Ionis Pharmaceuticals Main Business Overview
11.2.5 Ionis Pharmaceuticals Latest Developments
11.3 Alnylam
11.3.1 Alnylam Company Information
11.3.2 Alnylam RNA-based Therapeutics Drug Product Offered
11.3.3 Alnylam RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Alnylam Main Business Overview
11.3.5 Alnylam Latest Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen RNA-based Therapeutics Drug Product Offered
11.4.3 Biogen RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Biogen Main Business Overview
11.4.5 Biogen Latest Developments
11.5 Nippon Shinyaku
11.5.1 Nippon Shinyaku Company Information
11.5.2 Nippon Shinyaku RNA-based Therapeutics Drug Product Offered
11.5.3 Nippon Shinyaku RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Nippon Shinyaku Main Business Overview
11.5.5 Nippon Shinyaku Latest Developments
11.6 Sobi
11.6.1 Sobi Company Information
11.6.2 Sobi RNA-based Therapeutics Drug Product Offered
11.6.3 Sobi RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sobi Main Business Overview
11.6.5 Sobi Latest Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis RNA-based Therapeutics Drug Product Offered
11.7.3 Novartis RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Novartis Main Business Overview
11.7.5 Novartis Latest Developments
11.8 BioNTech
11.8.1 BioNTech Company Information
11.8.2 BioNTech RNA-based Therapeutics Drug Product Offered
11.8.3 BioNTech RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 BioNTech Main Business Overview
11.8.5 BioNTech Latest Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer RNA-based Therapeutics Drug Product Offered
11.9.3 Pfizer RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Pfizer Main Business Overview
11.9.5 Pfizer Latest Developments
11.10 Moderna Therapeutics
11.10.1 Moderna Therapeutics Company Information
11.10.2 Moderna Therapeutics RNA-based Therapeutics Drug Product Offered
11.10.3 Moderna Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Moderna Therapeutics Main Business Overview
11.10.5 Moderna Therapeutics Latest Developments
11.11 Jazz Pharmaceuticals
11.11.1 Jazz Pharmaceuticals Company Information
11.11.2 Jazz Pharmaceuticals RNA-based Therapeutics Drug Product Offered
11.11.3 Jazz Pharmaceuticals RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Jazz Pharmaceuticals Main Business Overview
11.11.5 Jazz Pharmaceuticals Latest Developments
11.12 CureVac
11.12.1 CureVac Company Information
11.12.2 CureVac RNA-based Therapeutics Drug Product Offered
11.12.3 CureVac RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 CureVac Main Business Overview
11.12.5 CureVac Latest Developments
11.13 Regulus Therapeutics
11.13.1 Regulus Therapeutics Company Information
11.13.2 Regulus Therapeutics RNA-based Therapeutics Drug Product Offered
11.13.3 Regulus Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Regulus Therapeutics Main Business Overview
11.13.5 Regulus Therapeutics Latest Developments
11.14 ProQR
11.14.1 ProQR Company Information
11.14.2 ProQR RNA-based Therapeutics Drug Product Offered
11.14.3 ProQR RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 ProQR Main Business Overview
11.14.5 ProQR Latest Developments
11.15 Secarna
11.15.1 Secarna Company Information
11.15.2 Secarna RNA-based Therapeutics Drug Product Offered
11.15.3 Secarna RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Secarna Main Business Overview
11.15.5 Secarna Latest Developments
11.16 MiNA Therapeutics
11.16.1 MiNA Therapeutics Company Information
11.16.2 MiNA Therapeutics RNA-based Therapeutics Drug Product Offered
11.16.3 MiNA Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 MiNA Therapeutics Main Business Overview
11.16.5 MiNA Therapeutics Latest Developments
11.17 Sylentis
11.17.1 Sylentis Company Information
11.17.2 Sylentis RNA-based Therapeutics Drug Product Offered
11.17.3 Sylentis RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Sylentis Main Business Overview
11.17.5 Sylentis Latest Developments
11.18 Arrowhead
11.18.1 Arrowhead Company Information
11.18.2 Arrowhead RNA-based Therapeutics Drug Product Offered
11.18.3 Arrowhead RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Arrowhead Main Business Overview
11.18.5 Arrowhead Latest Developments
11.19 Silence Therapeutics
11.19.1 Silence Therapeutics Company Information
11.19.2 Silence Therapeutics RNA-based Therapeutics Drug Product Offered
11.19.3 Silence Therapeutics RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Silence Therapeutics Main Business Overview
11.19.5 Silence Therapeutics Latest Developments
11.20 Dicerna
11.20.1 Dicerna Company Information
11.20.2 Dicerna RNA-based Therapeutics Drug Product Offered
11.20.3 Dicerna RNA-based Therapeutics Drug Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 Dicerna Main Business Overview
11.20.5 Dicerna Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. RNA-based Therapeutics Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. RNA-based Therapeutics Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. RNA-based Therapeutics Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 8. Global RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Table 9. RNA-based Therapeutics Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 11. Global RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Table 12. Global RNA-based Therapeutics Drug Revenue by Player (2021-2026) & ($ millions)
Table 13. Global RNA-based Therapeutics Drug Revenue Market Share by Player (2021-2026)
Table 14. RNA-based Therapeutics Drug Key Players Head office and Products Offered
Table 15. RNA-based Therapeutics Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global RNA-based Therapeutics Drug Market Size by Region (2021-2026) & ($ millions)
Table 19. Global RNA-based Therapeutics Drug Market Size Market Share by Region (2021-2026)
Table 20. Global RNA-based Therapeutics Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global RNA-based Therapeutics Drug Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas RNA-based Therapeutics Drug Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas RNA-based Therapeutics Drug Market Size Market Share by Country (2021-2026)
Table 24. Americas RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Table 26. Americas RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Table 28. APAC RNA-based Therapeutics Drug Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC RNA-based Therapeutics Drug Market Size Market Share by Region (2021-2026)
Table 30. APAC RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe RNA-based Therapeutics Drug Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe RNA-based Therapeutics Drug Market Size Market Share by Country (2021-2026)
Table 34. Europe RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa RNA-based Therapeutics Drug Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of RNA-based Therapeutics Drug
Table 40. Key Market Challenges & Risks of RNA-based Therapeutics Drug
Table 41. Key Industry Trends of RNA-based Therapeutics Drug
Table 42. Global RNA-based Therapeutics Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global RNA-based Therapeutics Drug Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global RNA-based Therapeutics Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global RNA-based Therapeutics Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 47. Sarepta Therapeutics RNA-based Therapeutics Drug Product Offered
Table 48. Sarepta Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals RNA-based Therapeutics Drug Product Offered
Table 53. Ionis Pharmaceuticals RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 57. Alnylam RNA-based Therapeutics Drug Product Offered
Table 58. Alnylam RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 62. Biogen RNA-based Therapeutics Drug Product Offered
Table 63. Biogen RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 67. Nippon Shinyaku RNA-based Therapeutics Drug Product Offered
Table 68. Nippon Shinyaku RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 72. Sobi RNA-based Therapeutics Drug Product Offered
Table 73. Sobi RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 77. Novartis RNA-based Therapeutics Drug Product Offered
Table 78. Novartis RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 82. BioNTech RNA-based Therapeutics Drug Product Offered
Table 83. BioNTech RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 87. Pfizer RNA-based Therapeutics Drug Product Offered
Table 88. Pfizer RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 92. Moderna Therapeutics RNA-based Therapeutics Drug Product Offered
Table 93. Moderna Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals RNA-based Therapeutics Drug Product Offered
Table 98. Jazz Pharmaceuticals RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 102. CureVac RNA-based Therapeutics Drug Product Offered
Table 103. CureVac RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 107. Regulus Therapeutics RNA-based Therapeutics Drug Product Offered
Table 108. Regulus Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 112. ProQR RNA-based Therapeutics Drug Product Offered
Table 113. ProQR RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 117. Secarna RNA-based Therapeutics Drug Product Offered
Table 118. Secarna RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 122. MiNA Therapeutics RNA-based Therapeutics Drug Product Offered
Table 123. MiNA Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 127. Sylentis RNA-based Therapeutics Drug Product Offered
Table 128. Sylentis RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 132. Arrowhead RNA-based Therapeutics Drug Product Offered
Table 133. Arrowhead RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 137. Silence Therapeutics RNA-based Therapeutics Drug Product Offered
Table 138. Silence Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 142. Dicerna RNA-based Therapeutics Drug Product Offered
Table 143. Dicerna RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
Table 1. RNA-based Therapeutics Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. RNA-based Therapeutics Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antisense Oligonucleotides (ASO)
Table 4. Major Players of siRNA
Table 5. Major Players of mRNA
Table 6. RNA-based Therapeutics Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 8. Global RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Table 9. RNA-based Therapeutics Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 11. Global RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Table 12. Global RNA-based Therapeutics Drug Revenue by Player (2021-2026) & ($ millions)
Table 13. Global RNA-based Therapeutics Drug Revenue Market Share by Player (2021-2026)
Table 14. RNA-based Therapeutics Drug Key Players Head office and Products Offered
Table 15. RNA-based Therapeutics Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global RNA-based Therapeutics Drug Market Size by Region (2021-2026) & ($ millions)
Table 19. Global RNA-based Therapeutics Drug Market Size Market Share by Region (2021-2026)
Table 20. Global RNA-based Therapeutics Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global RNA-based Therapeutics Drug Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas RNA-based Therapeutics Drug Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas RNA-based Therapeutics Drug Market Size Market Share by Country (2021-2026)
Table 24. Americas RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Table 26. Americas RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Table 28. APAC RNA-based Therapeutics Drug Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC RNA-based Therapeutics Drug Market Size Market Share by Region (2021-2026)
Table 30. APAC RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe RNA-based Therapeutics Drug Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe RNA-based Therapeutics Drug Market Size Market Share by Country (2021-2026)
Table 34. Europe RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa RNA-based Therapeutics Drug Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa RNA-based Therapeutics Drug Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa RNA-based Therapeutics Drug Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of RNA-based Therapeutics Drug
Table 40. Key Market Challenges & Risks of RNA-based Therapeutics Drug
Table 41. Key Industry Trends of RNA-based Therapeutics Drug
Table 42. Global RNA-based Therapeutics Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global RNA-based Therapeutics Drug Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global RNA-based Therapeutics Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global RNA-based Therapeutics Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Sarepta Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 47. Sarepta Therapeutics RNA-based Therapeutics Drug Product Offered
Table 48. Sarepta Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Sarepta Therapeutics Main Business
Table 50. Sarepta Therapeutics Latest Developments
Table 51. Ionis Pharmaceuticals Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 52. Ionis Pharmaceuticals RNA-based Therapeutics Drug Product Offered
Table 53. Ionis Pharmaceuticals RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Ionis Pharmaceuticals Main Business
Table 55. Ionis Pharmaceuticals Latest Developments
Table 56. Alnylam Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 57. Alnylam RNA-based Therapeutics Drug Product Offered
Table 58. Alnylam RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Alnylam Main Business
Table 60. Alnylam Latest Developments
Table 61. Biogen Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 62. Biogen RNA-based Therapeutics Drug Product Offered
Table 63. Biogen RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Biogen Main Business
Table 65. Biogen Latest Developments
Table 66. Nippon Shinyaku Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 67. Nippon Shinyaku RNA-based Therapeutics Drug Product Offered
Table 68. Nippon Shinyaku RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Nippon Shinyaku Main Business
Table 70. Nippon Shinyaku Latest Developments
Table 71. Sobi Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 72. Sobi RNA-based Therapeutics Drug Product Offered
Table 73. Sobi RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Sobi Main Business
Table 75. Sobi Latest Developments
Table 76. Novartis Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 77. Novartis RNA-based Therapeutics Drug Product Offered
Table 78. Novartis RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Novartis Main Business
Table 80. Novartis Latest Developments
Table 81. BioNTech Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 82. BioNTech RNA-based Therapeutics Drug Product Offered
Table 83. BioNTech RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. BioNTech Main Business
Table 85. BioNTech Latest Developments
Table 86. Pfizer Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 87. Pfizer RNA-based Therapeutics Drug Product Offered
Table 88. Pfizer RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Pfizer Main Business
Table 90. Pfizer Latest Developments
Table 91. Moderna Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 92. Moderna Therapeutics RNA-based Therapeutics Drug Product Offered
Table 93. Moderna Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. Moderna Therapeutics Main Business
Table 95. Moderna Therapeutics Latest Developments
Table 96. Jazz Pharmaceuticals Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 97. Jazz Pharmaceuticals RNA-based Therapeutics Drug Product Offered
Table 98. Jazz Pharmaceuticals RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. Jazz Pharmaceuticals Main Business
Table 100. Jazz Pharmaceuticals Latest Developments
Table 101. CureVac Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 102. CureVac RNA-based Therapeutics Drug Product Offered
Table 103. CureVac RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. CureVac Main Business
Table 105. CureVac Latest Developments
Table 106. Regulus Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 107. Regulus Therapeutics RNA-based Therapeutics Drug Product Offered
Table 108. Regulus Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Regulus Therapeutics Main Business
Table 110. Regulus Therapeutics Latest Developments
Table 111. ProQR Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 112. ProQR RNA-based Therapeutics Drug Product Offered
Table 113. ProQR RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. ProQR Main Business
Table 115. ProQR Latest Developments
Table 116. Secarna Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 117. Secarna RNA-based Therapeutics Drug Product Offered
Table 118. Secarna RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Secarna Main Business
Table 120. Secarna Latest Developments
Table 121. MiNA Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 122. MiNA Therapeutics RNA-based Therapeutics Drug Product Offered
Table 123. MiNA Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. MiNA Therapeutics Main Business
Table 125. MiNA Therapeutics Latest Developments
Table 126. Sylentis Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 127. Sylentis RNA-based Therapeutics Drug Product Offered
Table 128. Sylentis RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 129. Sylentis Main Business
Table 130. Sylentis Latest Developments
Table 131. Arrowhead Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 132. Arrowhead RNA-based Therapeutics Drug Product Offered
Table 133. Arrowhead RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 134. Arrowhead Main Business
Table 135. Arrowhead Latest Developments
Table 136. Silence Therapeutics Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 137. Silence Therapeutics RNA-based Therapeutics Drug Product Offered
Table 138. Silence Therapeutics RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 139. Silence Therapeutics Main Business
Table 140. Silence Therapeutics Latest Developments
Table 141. Dicerna Details, Company Type, RNA-based Therapeutics Drug Area Served and Its Competitors
Table 142. Dicerna RNA-based Therapeutics Drug Product Offered
Table 143. Dicerna RNA-based Therapeutics Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 144. Dicerna Main Business
Table 145. Dicerna Latest Developments
LIST OF FIGURES
Figure 1. RNA-based Therapeutics Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global RNA-based Therapeutics Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. RNA-based Therapeutics Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. RNA-based Therapeutics Drug Sales Market Share by Country/Region (2025)
Figure 8. RNA-based Therapeutics Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global RNA-based Therapeutics Drug Market Size Market Share by Type in 2025
Figure 10. RNA-based Therapeutics Drug in Neuromuscular Diseases
Figure 11. Global RNA-based Therapeutics Drug Market: Neuromuscular Diseases (2021-2026) & ($ millions)
Figure 12. RNA-based Therapeutics Drug in hATTR
Figure 13. Global RNA-based Therapeutics Drug Market: hATTR (2021-2026) & ($ millions)
Figure 14. RNA-based Therapeutics Drug in COVID-19
Figure 15. Global RNA-based Therapeutics Drug Market: COVID-19 (2021-2026) & ($ millions)
Figure 16. RNA-based Therapeutics Drug in Other
Figure 17. Global RNA-based Therapeutics Drug Market: Other (2021-2026) & ($ millions)
Figure 18. Global RNA-based Therapeutics Drug Market Size Market Share by Application in 2025
Figure 19. Global RNA-based Therapeutics Drug Revenue Market Share by Player in 2025
Figure 20. Global RNA-based Therapeutics Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas RNA-based Therapeutics Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC RNA-based Therapeutics Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe RNA-based Therapeutics Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa RNA-based Therapeutics Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas RNA-based Therapeutics Drug Value Market Share by Country in 2025
Figure 26. United States RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC RNA-based Therapeutics Drug Market Size Market Share by Region in 2025
Figure 31. APAC RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Figure 33. China RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe RNA-based Therapeutics Drug Market Size Market Share by Country in 2025
Figure 40. Europe RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa RNA-based Therapeutics Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 59. United States RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 63. China RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 67. India RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 70. France RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 71. UK RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 78. Global RNA-based Therapeutics Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global RNA-based Therapeutics Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 1. RNA-based Therapeutics Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global RNA-based Therapeutics Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. RNA-based Therapeutics Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. RNA-based Therapeutics Drug Sales Market Share by Country/Region (2025)
Figure 8. RNA-based Therapeutics Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global RNA-based Therapeutics Drug Market Size Market Share by Type in 2025
Figure 10. RNA-based Therapeutics Drug in Neuromuscular Diseases
Figure 11. Global RNA-based Therapeutics Drug Market: Neuromuscular Diseases (2021-2026) & ($ millions)
Figure 12. RNA-based Therapeutics Drug in hATTR
Figure 13. Global RNA-based Therapeutics Drug Market: hATTR (2021-2026) & ($ millions)
Figure 14. RNA-based Therapeutics Drug in COVID-19
Figure 15. Global RNA-based Therapeutics Drug Market: COVID-19 (2021-2026) & ($ millions)
Figure 16. RNA-based Therapeutics Drug in Other
Figure 17. Global RNA-based Therapeutics Drug Market: Other (2021-2026) & ($ millions)
Figure 18. Global RNA-based Therapeutics Drug Market Size Market Share by Application in 2025
Figure 19. Global RNA-based Therapeutics Drug Revenue Market Share by Player in 2025
Figure 20. Global RNA-based Therapeutics Drug Market Size Market Share by Region (2021-2026)
Figure 21. Americas RNA-based Therapeutics Drug Market Size 2021-2026 ($ millions)
Figure 22. APAC RNA-based Therapeutics Drug Market Size 2021-2026 ($ millions)
Figure 23. Europe RNA-based Therapeutics Drug Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa RNA-based Therapeutics Drug Market Size 2021-2026 ($ millions)
Figure 25. Americas RNA-based Therapeutics Drug Value Market Share by Country in 2025
Figure 26. United States RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC RNA-based Therapeutics Drug Market Size Market Share by Region in 2025
Figure 31. APAC RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Figure 32. APAC RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Figure 33. China RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 37. India RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe RNA-based Therapeutics Drug Market Size Market Share by Country in 2025
Figure 40. Europe RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Figure 41. Europe RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Figure 42. Germany RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. France RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. UK RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa RNA-based Therapeutics Drug Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa RNA-based Therapeutics Drug Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa RNA-based Therapeutics Drug Market Size Market Share by Application (2021-2026)
Figure 50. Egypt RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries RNA-based Therapeutics Drug Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 56. APAC RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 57. Europe RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 59. United States RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 60. Canada RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 61. Mexico RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 62. Brazil RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 63. China RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 64. Japan RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 65. Korea RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 67. India RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 68. Australia RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 69. Germany RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 70. France RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 71. UK RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 72. Italy RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 73. Russia RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 74. Egypt RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 75. South Africa RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 76. Israel RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 77. Turkey RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
Figure 78. Global RNA-based Therapeutics Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global RNA-based Therapeutics Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries RNA-based Therapeutics Drug Market Size 2027-2032 ($ millions)
